The goal of this clinical trial is to learn about whether it is safe to omit dissection of the No.253 lymph nodes in mid and low rectal cancer surgery. The main question it aims to answer is that if it is possible to achieve the same long-term survival with and without the dissection of the No.253 lymph node in mid and low rectal cancer surgery. Participants will underwent laparoscopic rectal radical resection with or without the dissection of the No.253 lymph node.
Patient age between 18-75 years.
Colonic biopsy pathology confirms adenocarcinoma.
At initial treatment, colonoscopy and imaging diagnose the tumor's lower edge as less than or equal to 7cm from the anus.
At initial treatment, imaging diagnoses the tumor T stage as less than or equal to 3.
Previous history of malignant colorectal tumors.
Colonic biopsy pathology reveals mucinous adenocarcinoma or signet ring cell carcinoma.
Imaging diagnosis of distant metastasis.
Patients who have undergone multiple abdominal-pelvic surgeries or have extensive abdominal adhesions.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lead sponsor
Peking Union Medical College Hospital
Collaborator
China-Japan Friendship Hospital
Collaborator
Chinese PLA General Hospital
Collaborator
Ruijin Hospital
Collaborator
Fudan University
Collaborator
West China Hospital
Collaborator
Peking University Cancer Hospital & Institute
Collaborator